Nested Therapeutics

40 posts

Nested Therapeutics banner
Nested Therapeutics

Nested Therapeutics

@nestedtx

Nested aims to advance precision oncology medicine by finding new driver mutations hiding in plain sight to reach a broader group of patients.

Cambridge, Massachusetts Joined Mart 2022
11 Following121 Followers
Nested Therapeutics retweeted
Cancer Discovery
Cancer Discovery@CD_AACR·
Watch first author Meagan B. Ryan discuss her research article, NST-628 is a novel and potent pan-RAF-MEK inhibitor, published simultaneously at #AACR24: vimeo.com/932606757/4d0b… @nestedtx
Cancer Discovery@CD_AACR

Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh @nestedtx

English
0
4
11
7K
Nested Therapeutics retweeted
Cancer Discovery
Cancer Discovery@CD_AACR·
Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh @nestedtx
Cancer Discovery tweet media
English
1
11
25
10.7K
Nested Therapeutics retweeted
Elizabeth McKenna
Elizabeth McKenna@ElizSMcKenna·
Congratulations to Klaus Hoeflich and co-authors at @nestedtx on this simultaneous #AACR24 publication in @CD_AACR!
Elizabeth McKenna tweet media
Cancer Discovery@CD_AACR

Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh @nestedtx

English
0
5
10
2.2K
Nested Therapeutics
Nested Therapeutics@nestedtx·
Yesterday at AACR, we unveiled the preclinical data on our lead program, NST-628, during an oral presentation as part of the “New Drugs on the Horizon” series. For more insights, visit our website and stay tuned for more updates! nestedtx.com/wp-content/upl…
Nested Therapeutics tweet media
English
0
0
3
79
Nested Therapeutics
Nested Therapeutics@nestedtx·
We're proud to announce the FDA clearance of our IND Application for NST-628. Additionally, our CSO, will present pre-clinical data on NST-628 at the “New Drugs on the Horizon” Series at the 2024 AACR Annual Meeting. Stay tuned for more updates! nestedtx.com
English
0
1
5
1.1K
Nested Therapeutics
Nested Therapeutics@nestedtx·
Today, we announce the appointment of three members to our board of directors. “We look forward to partnering with them as we continue to build our pipeline and advance our first program into the clinic this year.” - Darrin Miles, CEO nestedtx.com/wp-content/upl…
English
0
0
0
105
Nested Therapeutics
Nested Therapeutics@nestedtx·
We're excited to be featured in “Precision Oncology News” highlighting our co-founders, innovative platform and growing pipeline. Our lead compound NST-628, is anticipated to enter clinical trials in early 2024. Read more about us & the compelling science here!
Nested Therapeutics tweet mediaNested Therapeutics tweet mediaNested Therapeutics tweet media
English
0
0
2
129
Nested Therapeutics
Nested Therapeutics@nestedtx·
Happy #Thanksgiving from all of us at Nested Tx! As we head into the holiday season, let's take a moment to unwind and reflect on the impactful contributions we make every day. May this time be filled with relaxation, joy, and moments of #gratitude with loved ones!
Nested Therapeutics tweet media
English
0
0
0
103
Nested Therapeutics
Nested Therapeutics@nestedtx·
A huge round of applause to our presenters for an exceptional job representing Nested Therapeutics at the AACR-NCI-EORTC Conference in Boston! The team’s passion, expertise and dedication shined through as they showcased our strides made with NST-628. #PrecisionMedicine
Nested Therapeutics tweet media
English
0
0
0
189
Nested Therapeutics
Nested Therapeutics@nestedtx·
Today, at the 2023 AACR-NCI-EORTC Conference, we unveiled the first preclinical data on the mechanism of action, efficacy and brain penetrance of our lead candidate, NST-628, a mechanistically novel non-degrading molecular glue targeting multiple nodes in the RAS/MAPK pathway.
English
1
0
0
273
Nested Therapeutics retweeted
Arvin Dar
Arvin Dar@DarArvin·
Thanks @NatureBiotech for the great writeup! What an honor to be alongside stellar and dedicated founders, amazing investors and board, and the rigorous and relentless group of drug hunters that make up @nestedtx!
Nature Biotechnology@NatureBiotech

Next on our list of the best #NBTAcademicStartups spun out from academic institutions in 2022 are Cartography Biosciences and Nested Therapeutics, two startups taking a deep dive into cancer genomes to unearth new therapeutic targets nature.com/articles/d4158…

English
1
3
39
22.2K
Nested Therapeutics
Nested Therapeutics@nestedtx·
Nested Therapeutics will be presenting preclinical data from its lead candidate, NST-628, at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023. You can read more about it below.
English
1
1
2
558

Discover

@CD_AACR @NewEnglandVC @NatureBiotech @elonmusk @BarackObama @taylorswift13 @cristiano @BillGates